A Phase 2 interventional study of Seltorexant and Placebo in Alzheimer Disease, sponsored by Janssen Research & Development, LLC. Completed at 25 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Alzheimer Disease by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · Johnson & Johnson.
Among the 61 studies in Alzheimer Disease by Johnson & Johnson, this one is the 30th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 2, and was the 59th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →1 of the 61 studies in Alzheimer Disease by Johnson & Johnson is open now, in 10 countries. Recruiting first, the newest first:
Intra-Cellular Therapies, Inc. · Sites in United States, Bulgaria, Croatia and 7 more countries
Ages 55+
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 8 · Phase 3 25 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 108 across the 50 interventional studies, 1,109 across the 10 observational. Of the 59 that completed or were terminated, 9 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Alzheimer Disease by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06544616Janssen Pharmaceutica N.V., BelgiumA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | 2026-12-22 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies in Alzheimer Disease by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single oral dose of seltorexant 20 milligrams (mg) tablet once daily from Day 1 to Day 42.
Drug: Seltorexant
Participants will receive single oral dose of matching placebo tablet once daily from Day 1 to Day 42.
Drug: Placebo
Seltorexant 20 mg will be administered orally as a tablet.
Also known as: JNJ-42847922
Matching placebo will be administered orally as a tablet.
Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand 1
The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.
Time frame: Baseline (Day 1) and Day 43
Change From Baseline in NPI-C A+A at Day 43: Analyzed Under Estimand 2
The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on the basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.
Time frame: Baseline (Day 1) and Day 43
Change From Baseline in Cohen-Mansfield Agitation Inventory- Community Version (CMAI-C) Total Score at Day 43
The CMAI-C, 37-item scale, measured the ability of a drug to reduce overall frequency of agitation symptoms, including aggressive behaviors. Individual items were rated by the clinician on a scale of 1 (never) to 7 (several times per hour) in which higher score represented the most frequent for each item assessed. CMAI-C total score was a sum of all categories that ranged from 37 (never) to 259 (several times), where higher score indicated greater severity.
Time frame: Baseline (Day 1) and Day 43
Change From Baseline in Sleep Disorder Inventory (SDI) Average Total Score at Day 43
SDI: based on caregiver (CG) interview and expanded version of item 11 (night-time behavioral disturbances) of NPI-12. It described frequency, severity and CG burden of sleep-disturbed behaviors for period prior to its administration. It consisted of 7 sub-questions from NPI-12 sleep disturbance item. Each sub-question was made into separate questions with frequency, severity, and CG distress rated with respect to participant. SDI score derived after CG rated frequency, severity of each of 7 separate sleep disturbance symptoms. CG distress ratings were not part of SDI total score, but distress was measured. Frequency scored on scale of 0 (not present) to 4 (once or more per day), severity scored on scale of 0 (not present) to 3 (occurrence of nighttime behaviors) and CG distress rated on scale of 0 (not at all) to 5 (extremely). SDI average total score=average frequency of item 1 to 7 multiplied with average severity of items 1 to 7; ranged from 0 to 12; higher score=greater severity.
Time frame: Baseline and Day 43
Observed Plasma Concentrations of Seltorexant and Its Metabolite (M12)
The pharmacokinetic (PK) sample collection was done based on the availability of the participants either on Day 15 or 43 and thus collected data were analyzed and summary data were reported in this outcome measure. Plasma samples were analyzed using liquid chromatography/mass spectrometry/mass spectrometry (LC-MS/MS) method.
Time frame: Either Day 15 (8 and 14 hours post dose on night of Day 14) or Day 43 (8 and 14 hours post dose on night of Day 42)
| Milestone | DB: Placebo | DB: Seltorexant | Follow-up (FU): Placebo | FU: Seltorexant |
|---|---|---|---|---|
| Started | 44 | 44 | 0 | 0 |
| Treated | 42 | 43 | 0 | 0 |
| Completed | 39 | 35 | 0 | 0 |
| Not completed | 5 | 9 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Protocol-specified withdrawal criterion met | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Withdrew: Randomized but not treated | 2 | 1 | 0 | 0 |
| Milestone | DB: Placebo | DB: Seltorexant | Follow-up (FU): Placebo | FU: Seltorexant |
|---|---|---|---|---|
| Started | 0 | 0 | 39 | 38 |
| Completed | 0 | 0 | 39 | 34 |
| Not completed | 0 | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 3 |
The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.
| Score on a scale | DB: Placebo | DB: Seltorexant |
|---|---|---|
| Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand 1 | -9.6 ± 8.35 | -13.4 ± 9.31 |
The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on the basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.
| Score on a scale | DB: Placebo | DB: Seltorexant |
|---|---|---|
| Change From Baseline in NPI-C A+A at Day 43: Analyzed Under Estimand 2 | -9.6 ± 8.25 | -13.4 ± 9.31 |
The CMAI-C, 37-item scale, measured the ability of a drug to reduce overall frequency of agitation symptoms, including aggressive behaviors. Individual items were rated by the clinician on a scale of 1 (never) to 7 (several times per hour) in which higher score represented the most frequent for each item assessed. CMAI-C total score was a sum of all categories that ranged from 37 (never) to 259 (several times), where higher score indicated greater severity.
| Score on a scale | DB: Placebo | DB: Seltorexant |
|---|---|---|
| Change From Baseline in Cohen-Mansfield Agitation Inventory- Community Version (CMAI-C) Total Score at Day 43 | -17.5 ± 18.67 | -20.3 ± 21.69 |
SDI: based on caregiver (CG) interview and expanded version of item 11 (night-time behavioral disturbances) of NPI-12. It described frequency, severity and CG burden of sleep-disturbed behaviors for period prior to its administration. It consisted of 7 sub-questions from NPI-12 sleep disturbance item. Each sub-question was made into separate questions with frequency, severity, and CG distress rated with respect to participant. SDI score derived after CG rated frequency, severity of each of 7 separate sleep disturbance symptoms. CG distress ratings were not part of SDI total score, but distress was measured. Frequency scored on scale of 0 (not present) to 4 (once or more per day), severity scored on scale of 0 (not present) to 3 (occurrence of nighttime behaviors) and CG distress rated on scale of 0 (not at all) to 5 (extremely). SDI average total score=average frequency of item 1 to 7 multiplied with average severity of items 1 to 7; ranged from 0 to 12; higher score=greater severity.
| Score on a scale | DB: Placebo | DB: Seltorexant |
|---|---|---|
| Change From Baseline in Sleep Disorder Inventory (SDI) Average Total Score at Day 43 | -0.8 ± 1.02 | -0.5 ± 0.90 |
The pharmacokinetic (PK) sample collection was done based on the availability of the participants either on Day 15 or 43 and thus collected data were analyzed and summary data were reported in this outcome measure. Plasma samples were analyzed using liquid chromatography/mass spectrometry/mass spectrometry (LC-MS/MS) method.
| nanograms per milliliter (ng/mL) | DB: Seltorexant |
|---|---|
| Total Seltorexant | 121 ± 156 |
| Total M12 | 141 ± 164 |
Collected over Double-blind (DB) Phase: From Day 1 up to Day 43; Follow up Phase: From Day 44 to Day 57. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Placebo | 0/44 (0%) | 0/42 (0%) | 4/42 (9.5%) |
| DB: Seltorexant | 0/44 (0%) | 1/43 (2.3%) | 6/43 (14%) |
| Follow-up (FU): Placebo | 0/39 (0%) | 0/39 (0%) | 0/39 (0%) |
| FU: Seltorexant | 0/38 (0%) | 1/38 (2.6%) | 2/38 (5.3%) |
| Event | DB: Placebo | DB: Seltorexant | Follow-up (FU): Placebo | FU: Seltorexant |
|---|---|---|---|---|
| Pancreatic Neuroendocrine TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/42 | 0/43 | 0/39 | 1/38 |
| Ischaemic StrokeNervous system disorders | 0/42 | 1/43 | 0/39 | 0/38 |
| Event | DB: Placebo | DB: Seltorexant | Follow-up (FU): Placebo | FU: Seltorexant |
|---|---|---|---|---|
| Malignant Biliary ObstructionHepatobiliary disorders | 0/42 | 0/43 | 0/39 | 1/38 |
| OrchitisInfections and infestations | 0/42 | 0/43 | 0/39 | 1/38 |
| Neck PainMusculoskeletal and connective tissue disorders | 0/42 | 0/43 | 0/39 | 1/38 |
| Tension HeadacheNervous system disorders | 0/42 | 0/43 | 0/39 | 1/38 |
| PruritusSkin and subcutaneous tissue disorders | 0/42 | 0/43 | 0/39 | 1/38 |
| NasopharyngitisInfections and infestations | 1/42 | 1/43 | 0/39 | 0/38 |
| ContusionInjury, poisoning and procedural complications | 1/42 | 0/43 | 0/39 | 0/38 |
| InjuryInjury, poisoning and procedural complications | 1/42 | 0/43 | 0/39 | 0/38 |
| HeadacheNervous system disorders | 1/42 | 0/43 | 0/39 | 0/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/42 | 0/43 | 0/39 | 0/38 |
Full analysis set included all randomized participants who took at least 1 dose of study intervention.
| Age, Continuous(years) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| Mean | 72.6 ± 7.75 | 73.4 ± 6.18 | 73 ± 6.97 |
| Age, Customized(Participants) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| Adults (18-64 years) | 7 | 2 | 9 |
| From 65 to 84 years | 35 | 40 | 75 |
| 85 years and over | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| Female | 26 | 28 | 54 |
| Male | 16 | 15 | 31 |
| Ethnicity (NIH/OMB)(Participants) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 43 | 82 |
| Not Hispanic or Latino | 3 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 37 | 41 | 78 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| UNITED STATES | 42 | 43 | 85 |
| Age Categorical(Participants) | DB: Placebo | DB: Seltorexant | Total |
|---|---|---|---|
| Adults (18-64 years) | 7 | 2 | 9 |
| From 65 to 84 years | 35 | 40 | 75 |
| 85 years and over | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from May 2022 to primary completion in Nov 2023, 17 months.
Results were first posted in Nov 2024, 1 year after primary completion.
Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 17 months is below that.
Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seltorexant
Janssen Research & Development, LLC →